DRUG
Amylin
The participants will receive continuous intravenous infusion of 6 μg/min of pramlintide (amylin) over 20 minutes.
Status
Not yet recruiting
Phase
Not applicable
Enrollment
21
Locations
1
Results
Not posted
Publications
7
Study summary
Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Amylin is a vasodilator released from nerve fibers within the trigeminovascular system, which is considered a key anatomical and physiological substrate in the pathogenesis of migraine and persistent post-traumatic headache (PTH). Persistent PTH attributed to mild traumatic brain injury frequently presents with migraine attacks, suggesting shared underlying mechanisms with migraine. This study aims to determine whether intravenous infusion of pramlintide, an analogue of amylin, can induce migraine-like headache in individuals with persistent post-traumatic headache. To test this hypothesis, we will conduct a randomized, double-blind, placebo-controlled, two-way crossover study.
Interventions
DRUG
The participants will receive continuous intravenous infusion of 6 μg/min of pramlintide (amylin) over 20 minutes.
DRUG
The participants will receive continuous intravenous infusion of 20 mL of placebo (isotonic saline) over 20 minutes.
Timeline
First posted
Jan 14, 2026
Study start
Feb 2026
Primary completion
Dec 2028
Study completion
Dec 2028
Results posted
Not reported
Registry updated
Jan 14, 2026
Outcomes
Incidence of migraine-like headache
Time frame · 12 hours
Difference in incidence of migraine-like headache (0 to 12 hours) between pramlintide and placebo.
Headache Intensity Scores
Time frame · 12 hours
Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between pramlintide and placebo.
Eligibility
Inclusion Criteria: * Age 18 to 65 years of age upon entry into screening * History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3) * ≥ 4 monthly headache days on average across the 3 months prior to screening * Provision of informed consent prior to initiation of any study-specific activities/procedures Exclusion Criteria: * \> 1 mild traumatic injury to the head * History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache) * History of moderate or severe injury to the head * History of whiplash injury * History of craniotomy * History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion * The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior * Female subjects of childbearing potential with a positive pregnancy test during any study visit * Cardiovascular disease of any kind, including cerebrovascular diseases * Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day * Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg) * Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion * Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start * Baseline headache intensity of \>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache) * Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache
Study locations
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Rigshospitalet Glostrup
Glostrup Municipality, Denmark
Publications
Related trials
University of Copenhagen · Healthy Adult Participants · Bone Physiology
Not applicable
Not yet recruiting
15
2026-07
Oregon Health and Science University · Type 1 Diabetes
Not applicable
Completed
33
2026-06
Boston University · Alzheimer Disease · Mild Cognitive Impairment
Early Phase 1
Active, not recruiting
57
2026-05
Esbjerg Hospital - University Hospital of Southern Denmark · Obesity · Appetite Regulation
Phase 2 / Phase 3
Withdrawn
0
2026-04
University Hospital, Gentofte, Copenhagen · Obesity & Overweight
Not applicable
Recruiting
18
2026-04
Danish Headache Center · Headache Disorders, Primary · Headache Disorders
Not applicable
Not yet recruiting
21
2026-01
McGill University Health Centre/Research Institute of the McGill University Health Centre · type1diabetes · Diabetes Mellitus, Type 1
Phase 2 / Phase 3
Unknown
30
2024-04
Xeris Pharmaceuticals · Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus
Phase 2
Completed
18
2024-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.